NI202000031A - Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 - Google Patents

Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3

Info

Publication number
NI202000031A
NI202000031A NI202000031A NI202000031A NI202000031A NI 202000031 A NI202000031 A NI 202000031A NI 202000031 A NI202000031 A NI 202000031A NI 202000031 A NI202000031 A NI 202000031A NI 202000031 A NI202000031 A NI 202000031A
Authority
NI
Nicaragua
Prior art keywords
pyrimidine
compounds
pirazolo
pirrolo
novelty
Prior art date
Application number
NI202000031A
Other languages
English (en)
Inventor
Koppitz Marcus
Siebeneicher Holger
Braeuer Nico
Pook Elisabeth
Rotgeri Andrea
Neuhaus Roland
Martin Fischer Oliver
Nagel Jens
James Davenport Adam
Lindsay Carr James
James Townsend Robert
Connelly Ursinyova Nina
Anne Parrott Shelley
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NI202000031A publication Critical patent/NI202000031A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención cubre compuestos de pirazolo-pirrolo-pirimidin-diona sustituidos (PPPD) de la fórmula general (I): en la cual R1, R2 y R3 son como se los define en esta memoria, métodos de preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos, y el uso de dichos compuestos para la fabricación de composiciones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en particular de enfermedades neurogénicas, como agente único en combinación con otros principios activos.
NI202000031A 2017-10-27 2020-04-24 Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 NI202000031A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17198769 2017-10-27

Publications (1)

Publication Number Publication Date
NI202000031A true NI202000031A (es) 2020-08-28

Family

ID=60190695

Family Applications (1)

Application Number Title Priority Date Filing Date
NI202000031A NI202000031A (es) 2017-10-27 2020-04-24 Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3

Country Status (25)

Country Link
US (1) US11319324B2 (es)
EP (1) EP3700907B1 (es)
JP (1) JP7250011B2 (es)
KR (1) KR20200078567A (es)
CN (1) CN111527090B (es)
AU (1) AU2018354777A1 (es)
BR (1) BR112020008122B1 (es)
CA (1) CA3080249A1 (es)
CL (1) CL2020001107A1 (es)
CO (1) CO2020005065A2 (es)
CR (1) CR20200174A (es)
CU (1) CU20200038A7 (es)
DK (1) DK3700907T3 (es)
DO (1) DOP2020000100A (es)
EA (1) EA202091003A1 (es)
EC (1) ECSP20023626A (es)
ES (1) ES2914377T3 (es)
IL (1) IL274036A (es)
JO (1) JOP20200100A1 (es)
MA (1) MA50439A (es)
MX (1) MX2020004981A (es)
NI (1) NI202000031A (es)
PH (1) PH12020550494A1 (es)
SG (1) SG11202003662XA (es)
WO (1) WO2019081343A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778311A (zh) * 2019-11-01 2021-05-11 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
JP2023506436A (ja) * 2019-12-10 2023-02-16 上▲海▼翰森生物医▲薬▼科技有限公司 ピラゾール含有多環式誘導体阻害剤、そのための調製方法、及びその用途
WO2022175514A1 (en) * 2021-02-22 2022-08-25 Bayer Aktiengesellschaft N-(pyridin-2-yl)-acetamides as p2x3 inhibitors
WO2023021328A1 (en) * 2021-08-17 2023-02-23 Bellus Health Cough Inc. Preparation of a p2x3 antagonist

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0425541A1 (en) 1988-07-21 1991-05-08 The Upjohn Company Pyrazolo-azolo-pyrimidine-diones
KR100260292B1 (ko) * 1995-09-28 2000-07-01 오쓰카 요시미쓰 진통제
CN1414848A (zh) 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Acat抑制剂对斑块破裂的预防
KR20090025261A (ko) 2006-06-23 2009-03-10 인사이트 코포레이션 Ｈｍ７４ａ 아고니스트로서의 퓨리논 유도체
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CA2838784A1 (en) * 2011-08-12 2013-02-21 F. Hoffmann-La Roche Ag Pyrazolo[3,4-c]pyridine compounds and methods of use
WO2013182519A1 (en) * 2012-06-04 2013-12-12 Universitaet Basel Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
US10314816B2 (en) 2012-06-08 2019-06-11 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
EP2945636B1 (en) * 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
US20210317128A1 (en) 2021-10-14
CA3080249A1 (en) 2019-05-02
PH12020550494A1 (en) 2021-01-11
ES2914377T3 (es) 2022-06-10
ECSP20023626A (es) 2020-06-30
EP3700907A1 (en) 2020-09-02
MA50439A (fr) 2021-05-19
CU20200038A7 (es) 2021-03-11
EA202091003A1 (ru) 2020-09-11
BR112020008122B1 (pt) 2022-11-01
CR20200174A (es) 2020-06-26
JOP20200100A1 (ar) 2020-05-06
US11319324B2 (en) 2022-05-03
JP7250011B2 (ja) 2023-03-31
CL2020001107A1 (es) 2020-10-23
DK3700907T3 (da) 2022-05-30
WO2019081343A1 (en) 2019-05-02
EP3700907B1 (en) 2022-03-09
IL274036A (en) 2020-06-30
MX2020004981A (es) 2020-08-24
SG11202003662XA (en) 2020-05-28
CN111527090A (zh) 2020-08-11
AU2018354777A1 (en) 2020-04-16
DOP2020000100A (es) 2020-09-15
KR20200078567A (ko) 2020-07-01
BR112020008122A2 (pt) 2020-11-03
JP2021500380A (ja) 2021-01-07
CO2020005065A2 (es) 2020-05-29
CN111527090B (zh) 2023-05-26

Similar Documents

Publication Publication Date Title
DOP2019000117A (es) Nuevos derivados de quinolina
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
DOP2020000023A (es) Nuevos derivados de quinolina
CL2017002650A1 (es) Compuestos novedosos
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
ECSP17073965A (es) Derivados de ciclohexano sustituido con amido
UY37789A (es) Nuevos derivados de azaquinolina
NI202000031A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
DOP2016000253A (es) Nuevos compuestos
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
UY37971A (es) Derivados de indol macrocíclicos sustituidos
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY37250A (es) Derivados macrocíclicos de indol
CL2020002891A1 (es) Nuevos derivados de quinolina
UY37832A (es) Dihidrooxadiazinonas
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
UY37032A (es) Compuestos de heteroarilbenzimidazol